Literature DB >> 29391151

Survivin regulated by autophagy mediates hyperglycemia-induced vascular endothelial cell dysfunction.

Yu-Xue Xu1, Caoxin Huang2, Minyi Liu2, Ningning Chen2, Wenting Chen2, Chen Yang2, Yan Zhao2, Xuejun Li3, Junguo Duan4, Suhuan Liu5, Shuyu Yang6.   

Abstract

Diabetic vascular complications are often defined by vascular endothelial lesions. However, as a plastic cell type, whether endothelial cells could transit from quiescence to hyper-active status and hamper vascular stability upon hyperglycemia stimulation and whether this process is involved in diabetic vascular complications remain obscure. Survivin has been identified as an anti-apoptotic protein in tumor or epithelial cells by either promoting proliferation or inhibiting apoptosis. Therefore, this study aims at investigating the effects of hyperglycemia on endothelial cell status and the potential involvement of survivin. We found that high glucose (25 mM) did not cause endothelial injuries, instead, it evidently promotes endothelial proliferation and tube formation capacity indicating endothelial cell dysfunction upon hyperglycemia characterized by its preference to hyper-active status. Concomitantly, an upregulation of survivin was detected accompanied by the key component elevations of autophagy pathway including LC3, Beclin1, and p62. YM155, a specific inhibitor of survivin, could abrogate hyperglycemia-induced endothelial hyper-activation. Application of the autophagy inhibitor (3MA) and agonist (rapamycin) supported that survivin could be as a downstream effect or of autophagy. Thus, our results suggested that survivin/autophagy axis a potential therapeutic target in treatment of diabetic vascular complications.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autophagy; Hyperglycemia; Survivin; Vascular endothelial cells

Mesh:

Substances:

Year:  2018        PMID: 29391151     DOI: 10.1016/j.yexcr.2018.01.037

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  3 in total

1.  Innovative therapeutic strategy using prostaglandin I2 agonist (ONO1301) combined with nano drug delivery system for pulmonary arterial hypertension.

Authors:  Tomomitsu Kanaya; Shigeru Miyagawa; Takuji Kawamura; Yoshiki Sakai; Kenta Masada; Nobutoshi Nawa; Hidekazu Ishida; Jun Narita; Koichi Toda; Toru Kuratani; Yoshiki Sawa
Journal:  Sci Rep       Date:  2021-03-31       Impact factor: 4.379

Review 2.  COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity.

Authors:  Kenneth Lundstrom; Altijana Hromić-Jahjefendić; Esma Bilajac; Alaa A A Aljabali; Katarina Baralić; Nagwa A Sabri; Eslam M Shehata; Mohamed Raslan; Ana Cláudia B H Ferreira; Ángel Serrano-Aroca; Murtaza M Tambuwala; Vladimir N Uversky; Vasco Azevedo; Khalid J Alzahrani; Khalaf F Alsharif; Ibrahim F Halawani; Fuad M Alzahrani; Debmalya Barh
Journal:  Cell Signal       Date:  2022-10-14       Impact factor: 4.850

3.  Molecular mechanisms of methylglyoxal-induced aortic endothelial dysfunction in human vascular endothelial cells.

Authors:  Jae Hyuk Lee; Amna Parveen; Moon Ho Do; Min Cheol Kang; Silvia Yumnam; Sun Yeou Kim
Journal:  Cell Death Dis       Date:  2020-05-28       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.